BCL2L1 and cancer: Doxorubicin (Dox) treatment reduces cell viability and increases the number of senescent cancer cells, which show elevated levels of p16INK4a, enhanced expression of Bcl-xL and Bim and reduced expression of Bax, Bak, Bid and Puma [23].